Skip to main content
main-content

01.12.2014 | Short report | Ausgabe 1/2014 Open Access

Clinical and Translational Medicine 1/2014

Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma

Zeitschrift:
Clinical and Translational Medicine > Ausgabe 1/2014
Autoren:
Dagmar Riemann, Sabine Hase, Kersten Fischer, Barbara Seliger
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​2001-1326-3-13) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DR was responsible for conception and design of experiments, for analysis and interpretation of data, as well as for drafting the manuscript. SH carried out the flow cytometric acquisition of data and the analysis of data via SPSS. KF collected clinical data of patients. BS revised the manuscript and discussed data. All authors read and approved the final manuscript.

Abstract

Background

Neutrophil-to-lymphocyte ratio (NLR) has been shown to be a predictor of patients’ outcome for several types of malignancies.

Findings

Using multicolor flow cytometry we searched for predictive markers to monitor blood immune cells in patients with renal cell carcinoma undergoing surgery of the primary tumor. Due to a high standard deviation, pre-surgery NLR values did not significantly differ between tumor patients and the control group. In contrast, the granulocyte-to-dendritic cell (DC) ratio revealed significant higher values in tumor patients. Whereas NLR values did not differ between patients with early stage tumors and locally advanced tumors, the granulocyte/DC ratio was significantly different in these groups. Additionally, comparison of both ratios before and after tumor resection in the two groups “open surgery” and “laparoscopy” could demonstrate the suitability of granulocyte/DC ratio as a marker for immune monitoring.

Conclusions

Granulocyte/DC ratio may serve as a new putative biomarker for the immune monitoring of tumor patients.
Zusatzmaterial
Authors’ original file for figure 1
40169_2013_56_MOESM1_ESM.tif
Authors’ original file for figure 2
40169_2013_56_MOESM2_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Clinical and Translational Medicine 1/2014 Zur Ausgabe